Elucidating the specific pharmacological mechanism of action (MOA) of naturally happening compounds is often complicated. Though Tarselli et al. (sixty) designed the 1st de novo synthetic pathway to conolidine and showcased this naturally occurring compound correctly suppresses responses to each chemically induced and inflammation-derived pain, the